OSE Immunotherapeutics To Bolster R&D, Post-Janssen Option
The exercising by Janssen Biotech of an option to develop OSE Immunotherapeutics’ Phase II-ready antibody fragment for autoimmune and transplant-associated disorders will give an early boost to the French biotech that only completed a merger several weeks ago.
You may also be interested in...
Proximity is the key for future developments in science, Johnson and Johnson's UK innovation head Patrick Verheyen has told Scrip in a discussion surrounding the big pharma's 2014 goals for its globally scattered innovation centers, since their launch nearly a year ago.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.